News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Boston Scientific Corporation Heart Device Won’t Get Quick Review From FDA
March 26, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WSJ -- Regulators on Thursday said they won't speed up the review of manufacturing changes required for Boston Scientific Corp. to resume selling its implantable heart defibrillators.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Regulatory
Atara Climbs Amid Report of FDA Inconsistency Leading to Cell Therapy’s Rejection
February 26, 2026
·
1 min read
·
Tristan Manalac
Drug pricing
Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU
February 25, 2026
·
2 min read
·
Annalee Armstrong
Vaccines
Postponed ACIP Meeting Rescheduled for Mid-March
February 25, 2026
·
3 min read
·
Tristan Manalac
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
·
2 min read
·
Tristan Manalac
